Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Multiple Sclerosis and Related Disorders|August 3, 2024
Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administrationLiza M Y Gelissen, Sam Loveless, Alyssa A Toorop, et al.Journal of the Neurological Sciences|May 1, 2026
No interferon-beta antibodies in natalizumab-treated multiple sclerosis patients with progressive multifocal leukoencephalopathyLiza M Y Gelissen, Martijn T Wijburg, Eva M M Strijbis, et al.Multiple Sclerosis and Related Disorders|March 20, 2026
Safety and patient experiences with the natalizumab biosimilar in multiple sclerosis treatmentLiza M Y Gelissen, Eva M M Strijbis, Bob W van Oosten, et al.Journal of the Neurological Sciences|November 14, 2025
Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumabLiza M Y Gelissen, Laura Hogenboom, Alyssa A Toorop, et al.Annals of Neurology|February 10, 2023
Cerebral Small Vessel Disease Progression Increases Risk of Incident ParkinsonismMina A Jacob, Mengfei Cai, Mayra Bergkamp, et al.CPT: Pharmacometrics & Systems Pharmacology|March 20, 2025
Pharmacokinetic Model-Informed Precision Dosing of Natalizumab in Multiple SclerosisStefan P H van den Berg, Alyssa A Toorop, Femke Hooijberg, et al.Frontiers in Immunology|May 25, 2026
Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosisLiza M Y Gelissen, Stefan P H van den Berg, Alyssa A Toorop, et al.European Journal of Epidemiology|May 30, 2024
Assessing the validity of a Parkinson's care evaluation: the PRIME-NL studyLiza M Y Gelissen, Robin van den Bergh, Amir H Talebi, et al.Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosisLiza M Y Gelissen, Alyssa A Toorop, Pien M Schipper, et al.European Journal of Neurology|July 7, 2026
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of OcrelizumabLaura Hogenboom, Lisa G Schoof, Liza M Y Gelissen, et al.Pageof 2